Is Serina Therapeutics Inc (SER) overvalued? · rev $56.0K
Serina Therapeutics Inc (SER) is a biotechnology company listed on AMEX.
This page asks whether Serina Therapeutics Inc (SER) looks expensive on cached numbers — not a short thesis.
Latest reported SER revenue for 2024-12-31 was $56.0K. Net income was -$11.2M. Revenue was down 98.2% from 2023-12-31 to 2024-12-31. SER currently screens at market cap $29.7M.
SER currently screens at market cap $29.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SER 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SER stock page for the full model, not this heading.
Not investment advice.